
    
      Patients will be randomly allocated to either treatment arm in a 1:1 ratio. Following
      intervention, patients will be assessed at regular intervals until study completion at 6
      months post-discharge. Primary outcome is a composite of major complications and/or
      mortality, measured to 6 months post-discharge.
    
  